BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 18704985)

  • 1. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors.
    Freeman SS; Allen SW; Ganti R; Wu J; Ma J; Su X; Neale G; Dome JS; Daw NC; Khoury JD
    Cancer; 2008 Sep; 113(6):1453-61. PubMed ID: 18704985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.
    Ach T; Zeitler K; Schwarz-Furlan S; Baader K; Agaimy A; Rohrmeier C; Zenk J; Gosau M; Reichert TE; Brockhoff G; Ettl T
    Virchows Arch; 2013 Jan; 462(1):65-72. PubMed ID: 23242174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant expression of the human epidermal growth factor receptor 2 oncogene is not a common feature in osteosarcoma.
    Baumhoer D; Smida J; Specht K; Bink K; Quintanilla-Martinez L; Rosemann M; Siggelkow H; Nathrath WB; Atkinson MJ; Bielack S; Jundt G; Nathrath M
    Hum Pathol; 2011 Jun; 42(6):859-66. PubMed ID: 21292304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.
    Pollack IF; Hamilton RL; James CD; Finkelstein SD; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL;
    J Neurosurg; 2006 Nov; 105(5 Suppl):418-24. PubMed ID: 17328268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer.
    Ettl T; Baader K; Stiegler C; Müller M; Agaimy A; Zenk J; Kühnel T; Gosau M; Zeitler K; Schwarz S; Brockhoff G
    Br J Cancer; 2012 Feb; 106(4):719-26. PubMed ID: 22240798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma.
    Do SI; Jung WW; Kim HS; Park YK
    Int J Oncol; 2009 Mar; 34(3):797-803. PubMed ID: 19212684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.
    Williams MD; Roberts DB; Kies MS; Mao L; Weber RS; El-Naggar AK
    Clin Cancer Res; 2010 Apr; 16(8):2266-74. PubMed ID: 20371674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile.
    Lopez-Gines C; Gil-Benso R; Ferrer-Luna R; Benito R; Serna E; Gonzalez-Darder J; Quilis V; Monleon D; Celda B; Cerdá-Nicolas M
    Mod Pathol; 2010 Jun; 23(6):856-65. PubMed ID: 20305620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma.
    Hughes DP; Thomas DG; Giordano TJ; Baker LH; McDonagh KT
    Cancer Res; 2004 Mar; 64(6):2047-53. PubMed ID: 15026342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma.
    Toth J; Egervari K; Klekner A; Bognar L; Szanto J; Nemes Z; Szollosi Z
    Pathol Oncol Res; 2009 Jun; 15(2):225-9. PubMed ID: 18752056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
    Hohensee I; Lamszus K; Riethdorf S; Meyer-Staeckling S; Glatzel M; Matschke J; Witzel I; Westphal M; Brandt B; Müller V; Pantel K; Wikman H
    Am J Pathol; 2013 Jul; 183(1):83-95. PubMed ID: 23665199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas.
    de Muga S; Hernández S; Agell L; Salido M; Juanpere N; Lorenzo M; Lorente JA; Serrano S; Lloreta J
    Mod Pathol; 2010 May; 23(5):703-12. PubMed ID: 20208477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological and prognostic values of ErbB receptor family amplification in primary osteosarcoma.
    Huang Z; Wang SL; Chen H; Shen RK; Li XD; Huang QS; Wu CY; Weng DF; Lin JH
    Scand J Clin Lab Invest; 2019 Dec; 79(8):601-612. PubMed ID: 31663373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
    Holtkamp N; Malzer E; Zietsch J; Okuducu AF; Mucha J; Mawrin C; Mautner VF; Schildhaus HU; von Deimling A
    Neuro Oncol; 2008 Dec; 10(6):946-57. PubMed ID: 18650488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma.
    Ganti R; Skapek SX; Zhang J; Fuller CE; Wu J; Billups CA; Breitfeld PP; Dalton JD; Meyer WH; Khoury JD
    Mod Pathol; 2006 Sep; 19(9):1213-20. PubMed ID: 16729016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.
    Navarro L; Gil-Benso R; Megías J; Muñoz-Hidalgo L; San-Miguel T; Callaghan RC; González-Darder JM; López-Ginés C; Cerdá-Nicolás MJ
    Neuroscience; 2015 Jun; 297():243-51. PubMed ID: 25869624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
    Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
    J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
    Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
    J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-1908 is upregulated in human osteosarcoma and regulates cell proliferation and migration by repressing PTEN expression.
    Yuan H; Gao Y
    Oncol Rep; 2015 Nov; 34(5):2706-14. PubMed ID: 26328886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTEN in osteosarcoma: Recent advances and the therapeutic potential.
    Zheng C; Tang F; Min L; Hornicek F; Duan Z; Tu C
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188405. PubMed ID: 32827577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.